Case File
efta-efta01809662DOJ Data Set 10CorrespondenceEFTA Document EFTA01809662
Date
Unknown
Source
DOJ Data Set 10
Reference
efta-efta01809662
Pages
0
Persons
0
Integrity
No Hash Available
Loading PDF viewer...
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
"Barrett, Paul S"
jeffrey epstein
[email protected]> "Giu rida, David J" <
> NRG
Bonds
Jeffrey
B
NRG bonds look very interesting. We should buy $1MM of the NRG 7.625% 2018 at
ytw 7.50%.
B
We initiated coverage on the bonds in December with an OW (note attached)
B
NRG is an independent Power producer (IPP) with a generation blend of 44% nat gas,
33% coal, 16% oil, 5% Nuclear & 2% wind. B67% of Adjusted EBITDA comes from
wholesale generation
and 33% retail generation.B Think of the product mix as follows; NRG wants high
energy prices to sell long term contracts while they want low energy prices for their
retail business since they do not pass through cost savings to customers.
B
Running an asset valuation using very conservative assumptions, our analyst thinks
the bonds are well covered with a total asset valuation of
$12.4 billion implying 1.4x coverage on the unsecured notes.
We estimate NRG generates free cash flow before growth investments, share
repurchases, and dividends of $933 million in 2012, $738 million in
2013, and $1.04 billion in 2014.
B
In the attached note, our analyst said;
bThe company compares well to other IPPs in our high yield universe. NRG has the
most diversified generation portfolio in terms of both fuel type and generation type (i.e.,
baseload, peaking, etc.). The company is lower levered than all names but AES and
trades 170bp wide to Calpine, with whom it shares similar ratings. We recognize that
Calpine trades so tight because of its natural gas portfolio, but think that NRG trades
too
wide, in relation, given its strong credit profile. We also think NRG should trade more
than the current 100bp inside of GenOn given NRGbs stronger credit metrics, balanced
somewhat by its slightly lower (as a percentage of debt), but still strong liquidity.b
EFTA_R1_00168336
EFTA01809662
Technical Artifacts (1)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Email
[email protected]Related Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.